To get in touch, please contact:
David W. Robinson Kevin M. Keliher, CPA
Senior Corporate Development Officer Senior Financial Advisor
email: david.robinson@nucleobio.net kevin.keliher@nucleobio.net
mobile: 1-972-523-6793 mobile: 1-214-680-1403
Studies show that in the coming year, approximately 26,730 men in the United States alone will succumb to prostate cancer. However, through a simple, ground-breaking test, such numbers can be greatly reduced and a lot of deaths can be prevented. The current prostate cancer tests are filled with inaccuracies and usually, result in a high rate of misdiagnoses that lead to overtreatment of benign prostate disease. Due to such outcomes, health advocacy groups and physicians have advised patients to avoid getting screened at all. Prostac prevents all these issues by ensuring accurate and factual results each and every time, leading to more lives saved every year.
A staggering amount of 60,000 dollars per patient is spent by hospitals on unnecessary treatment. Furthermore, these treatments tend to lead to a lot of stresses and complications such as erectile dysfunction, urinary incontinence, and more. With a simple, state-of-the-art prostate test such as Prostac, we can greatly reduce or avoid the negative outcomes typical of current PSA screening tests. There would be no need, whatsoever, for radiation therapies, surgeries, and other procedures. Men can focus on their freedom without being subjected to the anxiety-inducing situations of watchful waiting and biopsies.
Want to Learn More?
CONTACT US